Regarding the Chaos of Counterfeit Certificates in Medical Aesthetics Exosomes, Jinbo Biotechnology Issues Latest Statement

Special Topic: Improving Consumer Quality — Focus on the 2026 “315 Gala”

Stock trading relies on Golden Kylin Analyst Reports—authoritative, professional, timely, comprehensive—helping you uncover potential thematic opportunities!

After the “3.15” Gala exposed serious issues in the medical aesthetics industry, such as illegal certification practices and false advertising of exosome products, Jinbo Biotech, a leading domestic company in the field of recombinant humanized collagen, has attracted attention.

A company representative told Shanghai Securities News that they have received numerous online and offline inquiries from consumers and partners. Jinbo Biotech issued a stern statement: zero tolerance for violations. The company also clarified and explained issues related to industry confusion and compliance standards to address market concerns.

This year’s “3.15” Gala mainly revealed violations in the exosome products sector of medical aesthetics. It was confirmed that certain products, such as “Qingcheng” produced by a biotech company, involved certification fraud—using a Class II medical device license for human-derived collagen and illegally adding exosome components.

It is known that exosomes are biologically active substances secreted during stem cell culture. Their mechanisms and clinical testing are not yet clearly understood in the medical and academic communities. Currently, no exosome-based drugs have been approved for sale in China, nor have any medical devices containing “exosomes” been approved for sale. However, some vendors are marketing such illegal products as “anti-aging miracle drugs.”

In response to this exposure and market doubts, Jinbo Biotech clearly stated in its declaration that it firmly supports national regulation and has zero tolerance for certification fraud. The statement pointed out that such certification fraud seriously violates the “Regulations on the Supervision and Administration of Medical Devices,” as substances not verified for safety are directly injected into the human body, endangering consumer health and damaging the reputation of compliant humanized collagen companies. The company pledged to support lawful crackdowns on such illegal activities and safeguard the safety bottom line of the medical aesthetics market.

Additionally, Jinbo Biotech explained the national medical device regulations: all medical devices injected into human dermis or bloodstream are classified as the highest-risk Class III devices, which must undergo rigorous pharmaceutical research, clinical trials, and review before obtaining the “Medical Device Registration Certificate (Class III).” Class II devices are only suitable for non-invasive or superficial use and must not be used for injections. The declaration emphasized that all exosome products claiming to be injectable, anti-aging, or disease-treating are illegal, as their safety and efficacy are not recognized by the state. Consumers should be highly cautious.

Jinbo Biotech also stated that it is currently the only domestic company approved by the National Medical Products Administration (NMPA) for three registration certificates for recombinant humanized collagen injection Class III medical devices, with registration numbers: GuoXieZhun 20213130488, GuoXieZhun 20233131245, and GuoXieZhun 20253130751. The relevant company officials said these certificates cover solutions, lyophilized fibers, and gels, representing the company’s long-term research and development efforts and rigorous clinical validation—proof of the safety and effectiveness of their products.

To help consumers avoid medical aesthetic traps, Jinbo Biotech reminds:

1. Recognize legal boundaries—Class II medical devices are not for injection; Class III certificates are the “entry permit” for injectable products.
2. Beware of certification fraud—carefully verify product names, ingredients, and applicable scopes to avoid being misled by illegal vendors using legitimate Class II certificates or adding illegal components like exosomes.
3. Check official information—before injection, visit the National Medical Products Administration website to verify product registration numbers and scope, ensuring the products are legal and compliant.

Author: Wu Bin

Sina Statement: This message is reprinted from Sina cooperative media. Sina.com publishes this article to disseminate more information and does not imply endorsement of its views or verification of its content. The article is for reference only and does not constitute investment advice. Investors operate at their own risk.

Massive information, precise analysis, all on Sina Finance APP

Editor: Song Yafang